Cytokinetics (CYTK) Statistics

Cytokinetics Inc (CYTK) is a biopharmaceutical company that focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company utilizes its expertise in muscle biology to develop innovative drugs that target the underlying causes of debilitating diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). By addressing the molecular mechanisms that regulate muscle contraction and relaxation, Cytokinetics aims to improve the lives of patients suffering from these devastating conditions.

In terms of valuation metrics, Cytokinetics Inc has a market capitalization of approximately $1.5 billion as of the latest available data. The company's stock statistics indicate that it has a 52-week high of $35.77 and a 52-week low of $9.31. This shows that the stock has experienced some volatility in the past year, but it has also demonstrated potential for growth. It is important to note that stock performance can be influenced by a variety of factors, including market conditions, industry trends, and company-specific events.